Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series
Background: Qingfei Paidu decoction (QFPDD) has been widely used in treating coronavirus disease 2019 (COVID-19) in China. However, studies on the treatment effect of COVID-19 patients and other respiratory diseases have not been well demonstrated. Our study aims to determine the treatment effect of...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.849598/full |
| _version_ | 1811292163154116608 |
|---|---|
| author | Xingyu Zong Ning Liang Jingya Wang Huizhen Li Dingyi Wang Yaxin Chen Haili Zhang Liwen Jiao An Li Guihui Wu Jike Li Mingxuan Wang Hongde Liu Zhang Liu Shusen Zhao Jin Huang Qiuhua Huang Xiaoyan Wang Jin Qin Yan Ma Yanping Wang Nannan Shi |
| author_facet | Xingyu Zong Ning Liang Jingya Wang Huizhen Li Dingyi Wang Yaxin Chen Haili Zhang Liwen Jiao An Li Guihui Wu Jike Li Mingxuan Wang Hongde Liu Zhang Liu Shusen Zhao Jin Huang Qiuhua Huang Xiaoyan Wang Jin Qin Yan Ma Yanping Wang Nannan Shi |
| author_sort | Xingyu Zong |
| collection | DOAJ |
| description | Background: Qingfei Paidu decoction (QFPDD) has been widely used in treating coronavirus disease 2019 (COVID-19) in China. However, studies on the treatment effect of COVID-19 patients and other respiratory diseases have not been well demonstrated. Our study aims to determine the treatment effect of QFPDD in combination with conventional treatment on COVID-19 patients and other respiratory diseases.Methods: This retrospective study recruited COVID-19 patients who were treated with QFPDD for at least two courses (6 days) from seven hospitals in five provinces from January 21 to March 18 2020. Demographic, epidemiological, clinical, laboratory, computed tomography characteristics, treatment, and outcome data were collected and analyzed. The improvements in clinical symptoms before and after QFPDD treatment were compared.Results: Eight COVID-19 patients were included in this study. Of them, six were males (75.0%). The median age of the patients was 66 (60–82) years. Four patients were classified as mild and moderate cases (50.0%); there were two severe cases (25.0%) and critical cases (25.0%). The most common symptom was cough (7 [87.5%]), followed by fever (6 [75.0%]), fatigue (4 [50.0%]), asthma (4 [50.0%]), and anorexia (3 [37.5%]). Abnormal findings included decrease in neutrophils (3 [37.5%]), lymphocytes (2 [25.0%]), alkaline phosphatase (3 [37.5%]), lactic dehydrogenase (4 [50.0%]), erythrocyte sedimentation rate (2 [25.0%]), and C-reactive protein (5 [83.3%]) at admission. After one course (3 days) of QFPDD, nasal obstruction and sore throat completely disappeared, and fever (5 [83.3%]), fatigue (2 [50.0%]), and cough (2 [28.6%]) were improved. After two courses (6 days), the fever disappeared completely in all patients, and the other symptoms showed a tendency to improve. In non-severe patients, 87.5% baseline symptoms completely disappeared. In severe patients, 61.1% of the baseline symptoms completely disappeared after patients were administered QFPDD for two courses. Of the abnormal indicators, 55.6% returned to normal levels. The median duration to complete fever recovery was 1.0 day. The median durations of viral shedding and hospitalization were 10.5 and 21.5 days, respectively. None of the patients worsened and died, and no serious adverse events occurred related to QFPDD during hospitalization.Conclusion: QFPDD combined with conventional treatment improved clinical symptoms in COVID-19 patients with other respiratory diseases, and no serious adverse reactions associated with QFPDD were observed. Larger sample studies confirm our findings in the future. |
| first_indexed | 2024-04-13T04:41:19Z |
| format | Article |
| id | doaj.art-3b3cf2b09cee46cd848515e33c04b7f1 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-13T04:41:19Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-3b3cf2b09cee46cd848515e33c04b7f12022-12-22T03:01:58ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-07-011310.3389/fphar.2022.849598849598Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case SeriesXingyu Zong0Ning Liang1Jingya Wang2Huizhen Li3Dingyi Wang4Yaxin Chen5Haili Zhang6Liwen Jiao7An Li8Guihui Wu9Jike Li10Mingxuan Wang11Hongde Liu12Zhang Liu13Shusen Zhao14Jin Huang15Qiuhua Huang16Xiaoyan Wang17Jin Qin18Yan Ma19Yanping Wang20Nannan Shi21Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaPublic Health Clinical Center of Chengdu, Chengdu, ChinaPublic Health Clinical Center of Chengdu, Chengdu, ChinaSuining Central Hospital, Suining, ChinaShijiazhuang Fifth Hosipital, Shijiazhuang, ChinaSuihua City First Hospital, Suihua, ChinaQiqihar Institute for The Prevention and Treatment of Infectious Diseases, Qiqihar, ChinaPeople’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, ChinaPeople’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, ChinaJinzhong Infectious Disease Hospital, Jinzhong, ChinaBeijing University of Chinese Medicine, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, ChinaBackground: Qingfei Paidu decoction (QFPDD) has been widely used in treating coronavirus disease 2019 (COVID-19) in China. However, studies on the treatment effect of COVID-19 patients and other respiratory diseases have not been well demonstrated. Our study aims to determine the treatment effect of QFPDD in combination with conventional treatment on COVID-19 patients and other respiratory diseases.Methods: This retrospective study recruited COVID-19 patients who were treated with QFPDD for at least two courses (6 days) from seven hospitals in five provinces from January 21 to March 18 2020. Demographic, epidemiological, clinical, laboratory, computed tomography characteristics, treatment, and outcome data were collected and analyzed. The improvements in clinical symptoms before and after QFPDD treatment were compared.Results: Eight COVID-19 patients were included in this study. Of them, six were males (75.0%). The median age of the patients was 66 (60–82) years. Four patients were classified as mild and moderate cases (50.0%); there were two severe cases (25.0%) and critical cases (25.0%). The most common symptom was cough (7 [87.5%]), followed by fever (6 [75.0%]), fatigue (4 [50.0%]), asthma (4 [50.0%]), and anorexia (3 [37.5%]). Abnormal findings included decrease in neutrophils (3 [37.5%]), lymphocytes (2 [25.0%]), alkaline phosphatase (3 [37.5%]), lactic dehydrogenase (4 [50.0%]), erythrocyte sedimentation rate (2 [25.0%]), and C-reactive protein (5 [83.3%]) at admission. After one course (3 days) of QFPDD, nasal obstruction and sore throat completely disappeared, and fever (5 [83.3%]), fatigue (2 [50.0%]), and cough (2 [28.6%]) were improved. After two courses (6 days), the fever disappeared completely in all patients, and the other symptoms showed a tendency to improve. In non-severe patients, 87.5% baseline symptoms completely disappeared. In severe patients, 61.1% of the baseline symptoms completely disappeared after patients were administered QFPDD for two courses. Of the abnormal indicators, 55.6% returned to normal levels. The median duration to complete fever recovery was 1.0 day. The median durations of viral shedding and hospitalization were 10.5 and 21.5 days, respectively. None of the patients worsened and died, and no serious adverse events occurred related to QFPDD during hospitalization.Conclusion: QFPDD combined with conventional treatment improved clinical symptoms in COVID-19 patients with other respiratory diseases, and no serious adverse reactions associated with QFPDD were observed. Larger sample studies confirm our findings in the future.https://www.frontiersin.org/articles/10.3389/fphar.2022.849598/fullCOVID-19respiratory diseasesQingfei Paidu decoctionTCMcase series |
| spellingShingle | Xingyu Zong Ning Liang Jingya Wang Huizhen Li Dingyi Wang Yaxin Chen Haili Zhang Liwen Jiao An Li Guihui Wu Jike Li Mingxuan Wang Hongde Liu Zhang Liu Shusen Zhao Jin Huang Qiuhua Huang Xiaoyan Wang Jin Qin Yan Ma Yanping Wang Nannan Shi Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series Frontiers in Pharmacology COVID-19 respiratory diseases Qingfei Paidu decoction TCM case series |
| title | Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series |
| title_full | Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series |
| title_fullStr | Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series |
| title_full_unstemmed | Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series |
| title_short | Treatment Effect of Qingfei Paidu Decoction Combined With Conventional Treatment on COVID-19 Patients and Other Respiratory Diseases: A Multi-Center Retrospective Case Series |
| title_sort | treatment effect of qingfei paidu decoction combined with conventional treatment on covid 19 patients and other respiratory diseases a multi center retrospective case series |
| topic | COVID-19 respiratory diseases Qingfei Paidu decoction TCM case series |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.849598/full |
| work_keys_str_mv | AT xingyuzong treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT ningliang treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT jingyawang treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT huizhenli treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT dingyiwang treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT yaxinchen treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT hailizhang treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT liwenjiao treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT anli treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT guihuiwu treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT jikeli treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT mingxuanwang treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT hongdeliu treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT zhangliu treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT shusenzhao treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT jinhuang treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT qiuhuahuang treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT xiaoyanwang treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT jinqin treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT yanma treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT yanpingwang treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries AT nannanshi treatmenteffectofqingfeipaidudecoctioncombinedwithconventionaltreatmentoncovid19patientsandotherrespiratorydiseasesamulticenterretrospectivecaseseries |